Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 19/20 | 0.87 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922983 | 0.94 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL21707846 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL7128242 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL7866788 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL23252094 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL22428378 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL22428407 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL22428377 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL7866764 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL7865429 | 0.93 | TLR4 (1.00) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287027-A1 | ADJUVANT WITH TLR4 AGONIST ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287027-A1 | ADJUVANT WITH TLR4 AGONIST ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287027-A1 | ADJUVANT WITH TLR4 AGONIST ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| CN-116056721-A | Adjuvants with TLR4 agonist activity | 住友制药株式会社 | 2023-05-02 | — | — | CN | disclosed |
| EP-4169527-A1 | ADJUVANT WITH TLR4 AGONIST ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287027-A1 | ADJUVANT WITH TLR4 AGONIST ACTIVITY | TLR4, TLR1, TLR9 | TLR4 1/4885LY96 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.